VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Dec. 20, 2005) - EnWave Corporation ("EnWave" or "the Company") (TSX VENTURE:ENW) is pleased to announce that the Company has received positive news on patentability of its technology for producing dry sponges and foams for biomaterials applications. The International Search Report and Written Opinion of the Patent Cooperation Treaty (PCT) international patent application process has found no reference that would impact on the novelty or patentability of any of the 19 claims of the application concerning methods for making foams. This patent application concerns Radiant Energy Vacuum (REV) medical foams intended for use as microbicides and drug delivery vehicles and was announced by EnWave in a press release on August 4, 2004. EnWave has an exclusive worldwide license to this technology from The University of British Columbia (UBC), as announced in a press release on December 3, 2004. No further action on these applications is required by EnWave or UBC until the National Phase of patent filing in individual jurisdictions prior to January 31, 2007.
"I am pleased to have received this further evidence of the inventiveness of our biomaterials technology," said Dr. Tim Durance. "Although this is only a preliminary screening of potential competing technologies, it gives us a green light for National Phase patent filings of our REV technology throughout the world in 2007."
EnWave is a research and development company developing commercial applications of vacuum microwave ("VM") technology using specially designed VM processing equipment. EnWave's mission is to lead the development of VM processing systems for industrial applications in the food, feed, pharmaceutical, nutraceutical and chemical industries. Applications of the technology enable manufacturers to produce innovative, high quality products that cannot be produced using current techniques. Many of the processes producing these products have been granted patents, recognizing their innovative nature.
This press release was prepared on behalf of the Board of Directors, which accepts full responsibility for its content.
ON BEHALF OF THE BOARD
Dr. Tim Durance, President, C.E.O. and Corporate Secretary
FOR FURTHER INFORMATION PLEASE CONTACT:
Dr. Tim Durance
(604) 806-6112 (FAX)